Meenakshi Anurag,Eric J. Jaehnig,Karsten Krug,Jonathan T. Lei,Erik J. Bergstrom,Beom-Jun Kim,Tanmayi D. Vashist,Anh Minh Tran Huynh,Yongchao Dou,Xuxu Gou,Chen Huang,Zhiao Shi,Bo Wen,Viktoriya Korchina,Richard A. Gibbs,Donna M. Muzny,Harshavardhan Doddapaneni,Lacey E. Dobrolecki,Henry Rodriguez,Ana I. Robles,Tara Hiltke,Michael T. Lewis,Julie R. Nangia,Maryam Nemati Shafaee,Shunqiang Li,Ian S. Hagemann,Jeremy Hoog,Bora Lim,C. Kent Osborne,D.R. Mani,Michael A. Gillette,Bing Zhang,Gloria V. Echeverria,George Miles,Mothaffar F. Rimawi,Steven A. Carr,Foluso O. Ademuyiwa,Shankha Satpathy,Matthew J. Ellis

Abstract:Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Figure 9 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figures 6-8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figures 1-4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Information from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential

Supplementary Figure 2 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Figure 4 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Tables 1-5 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Tables S1-S5 from Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Fig. 7 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Supplementary Figure 4 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers